Digital Intervention Postoperative Protocol

Sponsor
Oregon Health and Science University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04828109
Collaborator
(none)
80
1
4
9.2
8.7

Study Details

Study Description

Brief Summary

Postoperative recovery after head and neck surgery is complex, and often requires utilization of narcotic medications. The aim of this study is to evaluate reduction in pain and use of opioid medications through Virtual Reality (VR) and Fitbit wearable activity devices.

Condition or Disease Intervention/Treatment Phase
  • Device: Virtual Reality
  • Device: Fitbit
N/A

Detailed Description

Enhanced Recovery After Surgery (ERAS) protocols were introduced as a method to optimize perioperative patient care. Narcotic medications are frequently utilized in postoperative care, but these have risks including sedation or dependence. Non-pharmacologic measures for postoperative pain control may help limit the need for opioids in postoperative pain control.

Early mobilization is also important after surgery, however postoperative mobility is rarely monitored and relies on subjective reports.

The investigators will seek to examine the implementation of an ERAS protocol using VR and Fitbit wearable activity devices on postoperative recovery after head and neck surgery. This is a prospective, 4-arm, randomized controlled trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery
Actual Study Start Date :
Oct 25, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: VR and Fitbit

Daily VR use every 3 hours up to 30 minutes at a time and Fitbit daily step goal of 2,000 steps

Device: Virtual Reality
Use of any virtual reality experiences available

Device: Fitbit
Use of a Fitbit wearable activity device to track daily step goals.

Active Comparator: VR Only

Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.

Device: Virtual Reality
Use of any virtual reality experiences available

Active Comparator: Fitbit Only

Fitbit daily step goal of 2,000 steps.

Device: Fitbit
Use of a Fitbit wearable activity device to track daily step goals.

No Intervention: Control

Standard of care

Outcome Measures

Primary Outcome Measures

  1. Mean daily opioid use [through study completion, an average of 10 days]

    Mean daily opioid use will be assessed converted into milligram morphine equivalents (MME).

Secondary Outcome Measures

  1. Pain scores [through study completion, an average of 10 days]

    The Numeric Rating Scale (NRS) from 0 to 10 will be used to determine pain scores collected in the morning and evening each day. Scores will be averaged to obtain the daily pain score. We will also look at differences between AM and PM pain scores among the different cohorts. Scores will range from 0 (no pain) to 10 (worst pain)

  2. Anxiety [Before surgery and at study completion, an average of 10 days]

    The Generalized Anxiety Disorder 7-Item scale (GAD-7) will be used to determine preoperative and postoperative level of anxiety. Cut points of 5, 10, and 15 may represent mild, moderate, and severe levels of anxiety.

  3. Depression [Before surgery and at study completion, an average of 10 days]

    The Patient Health Questionaire-9 (PHQ-9) will be used to determine preoperative and postoperative level of depression. PHQ-9 scores can represent mild (<4), moderate (5-14), and severe (>20) depression.

  4. Sleep Quality [Before surgery and at study completion, an average of 10 days]

    The Insomnia Severity Index (ISI) will be used to determine preoperative and postoperative sleep quality. The ISI is a 7-item questionnaire evaluating severity of difficulty with sleep onset, sleep maintenance, early morning awakening, sleep dissatisfaction, interference in daytime functioning, noticeability of sleep difficulties by others, and distress from sleep difficulty. Items are rated on a 5-point Likert scale, and a total score ranges from 0 to 28.

  5. Patient experience and satisfaction [at study completion, an average of 10 days]

    A Visual Analogue Scale (VAS) will used to analyze patient satisfaction during hospitalization, and will be provided to patients on day of discharge. The VAS is a horizontal line that is 100-mm long, with no satisfaction (0) on the very left and extreme satisfaction on the very right (100).

  6. Disposition on discharge [at study completion, an average of 10 days]

    Data regarding disposition on discharge to home, home with home health, skilled nursing facility, inpatient rehabilitation facility, or other facility will be determined from the electronic medical record on the day of discharge.

  7. Length of hospital stay [at study completion, an average of 10 days]

    Length of stay will be calculated beginning from postoperative day one and will include the day of discharge.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • English speaking

  • 18 to 89 years of age.

  • Planned to undergo major head and neck surgery OHSU with an expected length of stay of two days or more.

  • Ability to understand goals of the study and willingness to sign a written informed consent document.

Exclusion Criteria:
  • Planned postoperative admission to the intensive care unit (ICU).

  • Social or psychiatric conditions that may interfere with compliance.

  • Isolation precautions.

  • Reconstruction, incisions, wounds, wound care, or injury that impact the ability to place on the VR headset or wear a Fitbit device around the wrist.

  • History of seizure or epilepsy.

  • History of vertigo or persistent dizziness.

  • Limitations that impair mobility.

  • Use of a walker or wheelchair at baseline.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oregon Health and Science University Portland Oregon United States 97239

Sponsors and Collaborators

  • Oregon Health and Science University

Investigators

  • Principal Investigator: Ryan Li, MD, Oregon Health and Science University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ryan Li, MD, Principal Investigator, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT04828109
Other Study ID Numbers:
  • 00021902
First Posted:
Apr 1, 2021
Last Update Posted:
Nov 1, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 1, 2021